This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mori, S. Articles by Nevins, J. R. Search for Related Content PubMed PubMed Citation Articles by Mori, S. Articles by Nevins, J. R.

Utilization of Pathway Signatures to Reveal Distinct Types of B Lymphoma in the Eµ-myc Model and Human Diffuse Large B-Cell Lymphoma

¹ Duke Institute for Genome Sciences and Policy; Departments of ² Molecular Genetics and Microbiology, ³ Pathology, and ⁴ Medicine, Duke University Medical Center, Durham, North Carolina; and ⁵ Department of Pharmacology and Toxicology, University of Utah, Salt Lake City, Utah

Requests for reprints: Joseph R. Nevins, Duke University, 2121 CIEMAS Building, 101 Science Drive, Durham, NC 27708. Phone: 919-684-2746; Fax: 919-681-8973; E-mail: nevin001{at}mc.duke.edu.

Key Words: oncogene • Eµ-myc model • MYC • Burkitt lymphoma • diffuse large B-cell lymphoma

The Eµ-myc transgenic mouse has provided a valuable model for the study of B-cell lymphoma. Making use of gene expression analysis and, in particular, expression signatures of cell signaling pathway activation, we now show that several forms of B lymphoma can be identified in the Eµ-myc mice associated with time of tumor onset. Furthermore, one form of Eµ-myc tumor with pre-B character is shown to resemble human Burkitt lymphoma, whereas others exhibit more differentiated B-cell characteristics and show similarity with human diffuse large B-cell lymphoma in the pattern of gene expression, as well as oncogenic pathway activation. Importantly, we show that signatures of oncogenic pathway activity provide further dissection of the spectrum of diffuse large B-cell lymphoma, identifying a subset of patients who have very poor prognosis and could benefit from more aggressive or novel therapeutic strategies. Taken together, these studies provide insight into the complexity of the oncogenic process and a novel strategy for dissecting the heterogeneity of B lymphoma. [Cancer Res 2008;68(20):8525–34]

This article has been cited by other articles:

				A. J. Gentles, A. A. Alizadeh, S.-I. Lee, J. H. Myklebust, C. M. Shachaf, B. Shahbaba, R. Levy, D. Koller, and S. K. Plevritis A pluripotency signature predicts histologic transformation and influences survival in follicular lymphoma patients Blood, October 8, 2009; 114(15): 3158 - 3166. [Abstract] [Full Text] [PDF]